Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure

Expert Review of Anticancer Therapy

Volumn 15, Issue 10, 2015, Pages 1183-1198

  Onesti, Concetta Elisa ^a   Romiti, Adriana ^a   Roberto, Michela ^a   Falcone, Rosa ^a   Marchetti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

advanced biliary tract cancers; advanced pancreatic cancer; metronomic chemotherapy; salvage chemotherapy; second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUPARLISIB; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GEMCITABINE ELAIDATE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GLUFOSFAMIDE; IMATINIB; IRINOTECAN; IRINOTECAN SUCROSOFATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; RUBITECAN; SELUMETINIB; SUNITINIB; TRAMETINIB; UNINDEXED DRUG;

BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CONTINUOUS INFUSION; DRUG TREATMENT FAILURE; HUMAN; LOW DRUG DOSE; METRONOMIC DRUG ADMINISTRATION; OVERALL SURVIVAL; PANCREAS CANCER; REVIEW; ANIMAL; BILIARY TRACT NEOPLASMS; DISEASE COURSE; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; BILIARY TRACT NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84942549617     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1081816     Document Type: Review

References (143)

1. Cardinale V, Wang Y, Carpino G, et al. The biliary tree-a reservoir of multipotent stem cells. Nat Rev Gastroenterol Hepatol 2012; 9: 231-40
2. Hidalgo M. Pancreatic Cancer. N Eng J Med 2010; 362: 1605-17
3. Artinyan A, Soriano PA, Prendergast C, et al. The anatomic location of pancreatic cancer is a prognostic factor for survival. HPB (Oxford) 2008; 10: 371-6
4. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26: 3496-502
5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350: 1200-10
6. Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01: Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer. J Clin Oncol 2013; 31: suppl;abstr4008
7. Hammel P, Huguet F, Van Laethem JL, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J Clin Oncol 2013; 31: suppl; abstr LBA4003
8. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13
9. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 2013; 31: 1640-8
10. Chuah B, Goh BC, Lee SC, et al. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci 102: 478-83. 2011
11. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 2011; 364: 1817-25
12. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Eng J Med 2013; 369: 1691-703
13. Moore MJ, Goldstein D, Hamm J, et al., Figer A. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007; 25: 1960-6
14. Burris HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005; 10: 183-90
15. Androulakis N, Syrigos K, Polyzos A, et al. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest 2005; 23: 9-12
16. Boeck S, Weigang-Köler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter Phase II trial. Ann Oncol 2007; 18: 745-51
17. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73: 221-7
18. Yi SY, Park YS, Kim HS, et al. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 1141-5
19. Takahara N, Nakai Y, Isayama H, et al. Uridine diphosphate glucuronosyltransferase 1 familypolypeptide A1 gene (UGT1A1) polymorphism are associated with toxicity and efficacy in Irinotecan monotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol 2013; 71: 85-92
20. Ko AH, Tempero MA, Shan YS, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer 2013; 109: 920-5
21. Saif MW, Syrigos K, Penney R, et al. Docetaxel second ine therapy in patients with advanced pancreatic cancer: a retrospective study. Anticancer Res 2010; 30: 2905-9
22. Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; 16: 539-45
23. Peddi PF, Cho M, Wang J, et al. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol 2013; 4: 370-3
24. Hosein PJ, De Lima Lopes G, Pastorini VH, et al. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol 2013; 36: 151-6
25. Li D, Pant S, Ryan DP, et al. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression. Pancreatology 2014; 14: 398-402
26. Morizane C, Okusaka T, Furuse J, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 313-19
27. Todaka A, Fukutomi A, Boku N, et al. S-1 monotherapy as second line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol 2010; 40: 567-72
28. Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67: 249-54
29. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and non cross resistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488-95
30. Reni M, Cereda S, Mazza E, et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 2008; 31: 145-50
31. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94: 481-5
32. Morizane C, Okusaka T, Ueno H, et al. Phase I/II study of gemcitabine as a fixed dose rate infusion and S1 combination therapy (FGS) in gemcitabine-refractory advanced pancreatic cancer. Cancer Chemother Pharmacol 2012; 69: 957-64
33. Tschoep-Lechner KE, Milani V, Berger F, et al. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. Int J Hyperthermia 2013; 29: 8-16
34. Stathopoulos GP, Boulikas T, Vougiouka M, et al. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol Rep 2006; 15: 1201-4
35. Giordano G, Milella M, Melisi D, et al. Nab-paclitaxel and gemcitabine in pretreated advanced pancreatic cancer patients: A multicentre retrospective analysis. Abs. ESMO 2014; 718P
36. Lim KH, Han SW, Oh DY, et al. Outcome of infusion 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012; 83: 57-66
37. Lee S, Oh SY, Kim BG, et al. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. Am J Clin Oncol 2009; 32: 348-52
38. Takahara N, Isayama H, Nakai Y, et al. A retrospective study of study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Cancer Chemother Pharmacol 2013; 72: 985-90
39. Pelzer U, Stieler J, Roll L, et al. Second-line therapy i refractory pancreatic cancer: results of a phase II study. Onkologie 2009; 32: 99-102
40. Novarino A, Satolli MA, Chiappino I, et al. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. Am J Clin Oncol 2009; 32: 44-8
41. Chung JW, Jang HW, Chung MJ, et al. Folfox4 as a rescue chemotherapy for gemcitabine-refrectory pancreatic cancer. Hepatogastroenterology 2013; 60: 363-7
42. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113: 2046-52
43. Berk V, Ozdemir N, Ozkan M, et al. XELOX vs. FOLFOX4 as second-line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 2012; 59: 2635-9
44. Gebbia V, Maiello E, Giuliani F, et al. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33: 461-4
45. Zaniboni A, Aitini E, Barni S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multi center phase II study. Cancer Chemother Pharmacol 2012; 69: 1641-5
46. Neuzillet C, Hentic O, Rousseau B, et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemctabine and platinum-salts. World J Gastroenterol 2012; 18: 4533-41
47. Cereda S, Reni M, Rognone A, et al. XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res 2010; 30: 4785-90
48. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80: 301-6
49. Kim YJ, Bang S, Park JY, et al. Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine refractory pancreatic cancer. Cancer Chemother Pharmacol 2009; 63: 529-33
50. Katapodis O, Polyzos A, Kentepozidis N, et al. Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Cancer Chemother Pharmacol 2011; 67: 361-8
51. Shi SB, Wang M, Niu ZX, et al. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer. Pancreatology 2012; 12: 475-9
52. Pino MS, Milella M, Gelibter A, et al. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. Oncology 2009; 76: 254-61
53. Cereda S, Reni M, Rognone A, et al. Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy 2011; 57: 156-61
54. Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785-91
55. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patents with advanced pretreated pancreatic cancer. Oncology 2004; 67: 93-7
56. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47: 1676-81
57. Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014; 32: 2423-9
58. Yoo C, Hwang JY, Kim JE, et al. A randomized phase II study of modified FOLFIRI 3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101: 1658-63
59. Azmy A, Abdelwahab S, Yassen M. Oxaliplatin and bolus-modulated 5-fluorouracil as a second-line treatment or advanced pancreatic cancer: can bolus regimens replace FOLFOX when considered for second line? ISRN Oncol 2013; 2013: 358538
60. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-4
61. Ohkawa S, Okusaka T, Isayama H, et al. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2015; 112: 1428-34
62. Ge F, Xu N, Bai Y, et al. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open label, multicenter, phase II study. Oncologist 2014; 19: 1133-4
63. Ciuleanu TE, Pavlovsky AV, Bodoky G, et al. A randomized phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 2009; 45: 1589-96
64. Chen LT, Von Hoff DD, Li CP, et al. Expanded analysis of napoli-1: phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol 2015; 33: suppl3;abstr234
65. Warsame R, Grothey A. Treatment option for advanced pancreatic cancer: a review. Exp Rev Anticancer Ther 2012; 12: 1327-36
66. Study of gemcitabine and Abraxane for pancreas cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02242409
67. Ignatiadis M, Polyzos A, Stathopoulos GP, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006; 71: 159-63
68. Brell JM, Matin K, Evans T, et al. Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology 2009; 76: 270-4
69. Renouf DJ, Tang PA, Hedley D, et al. A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer. Eur J Cancer 2014; 50: 1909-15
70. Propper D, Davidenko I, Bridgewater J, et al. Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma. Ann Oncol 2014; 25: 1384-90
71. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine refractory advanced pancreatic cancer. J Clin Oncol 2007; 25: 4787-92
72. Ko AH, Venook AP, Bergsland EK, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010; 66: 1051-7
73. Javle M, Shroff RT, Xiong H, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 2010; 10: 368
74. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009; 27: 193-8
75. Kordes S, Klümpen HJ, Waterman MJ, et al. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2015; 75: 1135-41
76. OReilly EM, Niedzwiecki D, Hall M, et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010; 15: 1310-19
77. Astsaturov IA, Meropol NJ, Alpaugh RK, et al. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol 2011; 34: 70-5
78. Bodoky G, Timcheva C, Spigel DR, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 2012; 30: 1216-23
79. Starling N, Hawkes EA, Chau I, et al. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Ann Oncol 2012; 23: 942-7
80. Carvajal RD, Tse A, Shah MA, et al. A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer. Pancreatology 2009; 9: 404-9
81. Bedard PL, Tabernero J, Janku FF, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK11202112) in patients with selected advanced solid tumors. Clin Cancer Res 2015; 21: 730-8
82. Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with GVAX Pancreas Prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccine for metastatic pancreatic cancer. J Clin Oncol 2015; 33: 1325-33
83. Glufosfamide versus 5-FU in second line metastatic pancreatic cancer. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01954992
84. Randomized study with oxaliplatin in 2nd line pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01121848
85. ®-1). Available from: https://clinicaltrials.gov/ct2/show/NCT01956812
86. Sasaki T, Isayama H, Nakai Y, et al. Improvement of prognosis for unresectable biliary tract cancer. World J Gastroenterol 2013; 19: 72-7
87. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy of biliary tract cancer: a systemic review and meta-analysis. J Clin Oncol 2012; 30: 1934-40
88. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Eng J Med 2010; 362: 1273-81
89. Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol 2010; 28: 4581-6
90. Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase-3 study. Lancet Oncol 2012; 13: 181-8
91. Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15: 819-28
92. Romiti A, DAntonio C, Zullo A, et al. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer 2012; 43: 396-404
93. Romiti A, Barucca V, Zullo A, et al. Tumours of ampulla of Vater: A case series and review of chemotherapy options. World J Gastrointest Oncol 2012; 4: 60-7
94. Sasaki T, Isayama H, Nakai Y, et al. Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs 2011; 29: 1488-93
95. Oh SY, Jeong CY, Hong SC, et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2011; 29: 1066-72
96. Sasaki T, Isayama H, Nakai Y, et al. A pilot study of salvage irinotecan monotherapy for advanced biliary tract cancer. Anticancer Res 2013; 33: 2619-22
97. Sasaki T, Isayama H, Nakai Y, et al. Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine. Invest New Drugs 2012; 30: 708-13
98. Lim KH, Han SW, Oh DY, et al. Outcome of infusion 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncology 2012; 83: 57-66
99. He S, Shen J, Sun X, et al. A phase II FOLFOX-4 regimen as second line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin. J Chemother 2014; 26: 243-7
100. Hwang IG, Jang JS, Oh SY, et al. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer. Cancer Chemother Pharmacol 2015; 75: 757-62
101. Yi JH, Thongprasert S, Lee J, et al. A Phase II study of sunitinib as a second line treatment in advanced biliary tract carcinoma: a multicentre, multinational study. Eur J Cancer 2012; 48: 196-201
102. Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a Phase II trial. Br J Cancer 2010; 102: 68-72
103. Buzzoni R, Pusceddu S, Bajetta E, et al. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II I.T.M.O. group study. Ann Oncol 2014; 25: 1597-603
104. Philip PA, Mahoney MR, Allmer LC, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006; 24: 3069-74
105. Rohrberg KS, Olesen RK, Pleiffer P, et al. Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers. Acta Oncol 2012; 51: 234-42
106. Guion-Dusserre JF, Lorgis V, Vincent J, et al. FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma. World J Gastroenterol 2015; 21: 2096-101
107. Paule B, Herelle MO, Rage E, et al. Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 2007; 72: 105-10
108. Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011; 29: 2357-6
109. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64: 777-83
110. Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer 2013; 49: 329-35
111. Andersen JB, Thorgeirsson SS. A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepat Oncol 2014; 1: 143-57
112. Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-25
113. Miyamoto M, Ojima H, Iwasaki M, et al. Prognostic significante of overexpression of c-MET oncoprotein in cholangiocarcinoma. Br J Cancer 2011; 105: 131-8
114. Romiti A, Cox MC, Sarcina I, et al. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Cancer Chemother Pharmacol 2013; 72: 13-33
115. Steinbild S, Arends J, Medinger M, et al. Metronomic antiangiogenetic therapy with capecitabine and celecoxib in advanced tumour patients-results of a phase II study. Onkologie 2007; 30: 629-35
116. Young SD, Whissel M, Noble JC, et al. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumours. Clin Cancer Res 2006; 12: 3092-8
117. Allegrini G, Desidero T, Barletta MT, et al. Clinical pharmacokinetic and pharmacodynamic evaluation of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012; 15: 275-86
118. Sun JF, Wu RR, Norris C, et al. Safety of chronic low-dose capecitabine as maintenance therapy in gastrointestinal cancers. Gastointest Cancer Res 2009; 3: 134-40
119. Miger J, Holmqvist A, Sun XF, et al. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol 2014; 31: 870
120. Romiti A, Onesti CE, Roberto M, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol 2015; 32: 496
121. Study of ruxolitinib in pancreatic cancer patients (RECAP). Available from: https://clinicaltrials.gov/ct2/show/NCT01423604
122. Selumetinib and Akt inhibitor MK2206 or mFOLFOX therapy comprising oxaliplatin and fluorouracil in treating patients with metastatic pancreatic cancer previously treated with chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT01658943
123. A study of MEK162 and AMG 479 in patients with selected solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01562899
124. Selumetinib and erlotinib hydrochloride in treating patients with locally advanced or metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01222689
125. Gemcitabine and pulse dose erlotinib in second line treatment of advanced pancreatic cancer. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02154737
126. Combination of irinotecan, oxaliplatin and cetuximab for locally advanced or metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00871169
127. Pilot trial of BMN 673, an oral PARP inhibitor, in patients with advanced solid tumors and deleterious BRCA mutations. Available from: https://clinicaltrials.gov/ct2/show/NCT01989546
128. Safety and efficacy study of PRI-724 plus gemcitabine in subjects with advanced or metastatic pancreatic adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01764477
129. Regorafenib plus gemcitabine in metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT02383433
130. A Phase 2, multicenter study of FOLFIRINOX followed by ipilimumab with allogenic GM-CSF transfected pancreatic tumor vaccine in the treatment of metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01896869
131. Immunotherapy using tumor infiltrating lymphocytes for patients with metastatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01174121
132. Phase II/pilot study of 2nd generation anti-CEA designer T cells in adenocarcinomas. Available from: https://clinicaltrials.gov/ct2/show/NCT01723306
133. Investigators initiated Phase II study for pancreatic cancer patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01659502
134. ® + 2nd-line FOLFOX in pancreatic liver mets. Available from: https://clinicaltrials.gov/ct2/show/NCT01581307
135. QYHJ Granules versus xeloda in metastatic pancreatic cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01796782
136. Open-label Phase 2 efficacy trial of cancer macrobeads in patients with treatment-resistant pancreatic or colorectal cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01053013
137. Efficacy and safety of L-asparaginase encapsulated in RBC combined with gemcitabine or FOLFOX in 2nd line for progressive metastatic pancreatic carcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02195180
138. Active symptom control alone or with mFOLFOX chemotherapy for locally advanced/metastatic biliary tract cancers (ABC06). Available from: https://clinicaltrials.gov/ct2/show/NCT01926236
139. XELOX in advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy. Available from: https://clinicaltrials.gov/ct2/show/NCT02350686
140. CAP7.1 for the treatment of advanced stage, therapy refractory lung and biliary tract tumors (CAP7-1). Available from: https://clinicaltrials.gov/ct2/show/NCT02094560
141. A Phase IIa study of the MEK inhibitor trametinib monotherapy in the treatment of biliary tract cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT01943864
142. Phase II study of refametinib, a MEK inhibitor, as second-line treatment in advanced biliary tract adenocarcinoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02346032
143. Phase II study of SPI-1620 in combination with docetaxel as a second-line to treat biliary cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01773785